ausbiz a.m

Grady Wulff on US Tech Rotation, Banking Earnings, and Growth Stocks

10 min Listen to the original
US TechBankingDefensive StocksLight and WonderNurxArcadia PharmaceuticalsAI RegulationEarnings

Summary

Grady Wulff discusses a rotation out of US tech stocks following midterm election results and AI regulatory concerns, contrasting this with Australia's defensive market shift. He highlights consumer staples outperformance and analyzes upcoming banking earnings, particularly CBA's net interest margins. Wulff identifies Light and Wonder as a value opportunity due to counter-cyclical gambling demand and strong cash flow. He also details growth drivers for Nurx and Arcadia Pharmaceuticals, citing rising drug sales and pipeline progress.

Key takeaways

  1. 1
    Light and Wonder trades at 9x EV to EBITDA, with gambling demand historically increasing during economic downturns.

    Unidentified speaker (speaker_2) · 6:03

Episode sections

  1. 0:14 – 1:11

    Market Context and US Tech Rotation

    Juliette Saly introduces the topic, noting US tech stocks have taken a significant hit due to AI regulation and data center investment concerns, with rotation into blue-chip and defensive stocks. Grady Wulff joins to discuss if Australia is becoming a safe haven or if the full impact of the global sell-off has yet to be felt.

  2. 1:11 – 2:56

    US Midterms and AI Regulatory Scrutiny

    Grady Wulff explains that the Nasdaq fell 3.4% last week due to midterm election results shifting Texas to a blue state, raising concerns about regulatory scrutiny on AI data centers. Investors are questioning whether high capital expenditures in AI will yield returns or if build-outs will stall.

  3. 2:56 – 4:38

    Australian Earnings and Defensive Shift

    Wulff contrasts Australia's low single-digit earnings growth (7-9%) with US earnings growth of 30.8%, noting Australian earnings face headwinds. However, defensive stocks and consumer staples outperformed last week, with consumer staples up 1.4%, as investors seek security amid high interest rates and economic pressure.

  4. 4:38 – 5:48

    Banking Sector Outlook and CBA Earnings

    Key earnings from ANZ, CBA, Westpac, and NAB are discussed, with Westpac and NAB already reporting job cuts. CBA, reporting on November 11th, is a focal point due to challenging times despite an $11 billion profit, with attention on net interest margins, mortgage competition, and provisions as lending growth drivers.

  5. 5:48 – 7:22

    Light and Wonder Investment Thesis

    Wulff highlights Light and Wonder as a buy, trading at 9x EV to EBITDA. He argues that gambling demand often increases during economic downturns. The company has strong cash flow, declining debt, and a diversified gaming business, with core operations expected to offset temporary weakness in its side play.

  6. 7:22 – 8:42

    Nurx and Arcadia Pharmaceuticals Growth

    Wulff discusses Nurx (likely ASX: NUR) and partner Arcadia Pharmaceuticals, noting Deubot sales for Rett syndrome treatment rose 39% to $140 million. Over 50% of the US has transitioned to a new powdered formula, and earnings were upgraded for two consecutive quarters. Arcadia reaffirmed a $700 million debut sales target for 2028.

  7. 8:42 – 9:57

    Nurx Pipeline and Future Growth

    Nurx is launching a drug in Germany, triggering a milestone payment. A second drug, NNZ251, is in Phase 3 trials for four neurodevelopmental disorders, with an expected market five times larger than the first drug. Wulff suggests these future earnings are not yet factored into the share price.

Claims worth verifying

US tech stocks have taken a significant hit due to AI regulation, data center investment concerns, and midterm election results shifting Texas to a blue state.

Unidentified speaker (speaker_1) ·0:21

How to verify: Check US stock market performance data for late October/early November 2026 and news reports on Texas midterm election results and subsequent regulatory announcements regarding AI infrastructure. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

The Nasdaq was down 3.4% last week.

Unidentified speaker (speaker_2) ·2:31

How to verify: Check historical Nasdaq Composite index performance data for the week ending November 7, 2026. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Australian earnings growth outlook is 7-9%, while US markets had 30.8% average earnings growth potential in their most recent results.

Unidentified speaker (speaker_2) ·3:16

How to verify: Review Australian Bureau of Statistics or major bank forecasts for Australian corporate earnings growth and compare with S&P 500 earnings growth reports for the relevant quarter. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Consumer staples outperformed last week with a 1.4% gain.

Unidentified speaker (speaker_2) ·3:36

How to verify: Check performance data for the S&P/ASX 200 Consumer Staples sector index for the week ending November 7, 2026. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

RBA raised rates last Tuesday.

Unidentified speaker (speaker_2) ·4:06

How to verify: Check Reserve Bank of Australia (RBA) press releases and meeting minutes for November 2026 to confirm the date and magnitude of any rate change. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

CBA reported an $11 billion profit.

Unidentified speaker (speaker_2) ·4:58

How to verify: Review Commonwealth Bank of Australia's (CBA) most recent half-year or full-year financial report available on the ASX or CBA investor relations page. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Primary source

Light and Wonder is trading at 9x EV to EBITDA.

Unidentified speaker (speaker_2) ·6:03

How to verify: Calculate Light and Wonder's Enterprise Value to EBITDA ratio using its current share price, market cap, debt, cash, and trailing twelve-month EBITDA from financial data providers like Bloomberg or Refinitiv. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Light and Wonder's free cash flow increased 33% and debt is declining.

Unidentified speaker (speaker_2) ·7:02

How to verify: Review Light and Wonder's latest quarterly or annual financial statements for changes in free cash flow and total debt levels. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Deubot sales for Rett syndrome treatment increased 39% to $140 million in Q3.

Unidentified speaker (speaker_2) ·7:42

How to verify: Check Arcadia Pharmaceuticals' or Nurx's latest quarterly earnings report or press release detailing Deubot sales figures. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Arcadia Pharmaceuticals reaffirmed a $700 million debut sales target for 2028.

Unidentified speaker (speaker_2) ·8:42

How to verify: Review Arcadia Pharmaceuticals' investor presentations, earnings calls, or press releases for the 2028 sales guidance for Deubot. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify Nasdaq performance and Texas midterm election results via SEC filings or financial news archives.
  • Check CBA's upcoming earnings release on November 11th for net interest margin trends and mortgage competition data.
  • Review Light and Wonder's latest annual report for EV/EBITDA valuation metrics and free cash flow statements.
  • Confirm Arcadia Pharmaceuticals' Deubot sales figures and $700 million 2028 sales target in their latest press releases.
  • Examine Nurx's clinical trial updates for NNZ251 Phase 3 progress and regulatory milestones in Germany.
  • Assess Australian banking sector provisions and refinancing rates through RBA reports and bank earnings calls.
Full transcriptexpand
0:13
Unidentified speaker (UNKNOWN): From
0:14
Unidentified speaker (speaker_0): Beringaroo Studios, this is Osby's AM.
0:21
Unidentified speaker (speaker_1): Good morning. It is Monday, the 9th of November. I'm Juliette Sali, Sale, and it'll be a fascinating story. start to the week for Australian investors. The ASX looking to outperform Wall Street as global markets grapple with growing uncertainty around AI regulation, data center investment, and the future of big tech. Now, US tech stocks have taken a significant hit,
0:41
Unidentified speaker (speaker_1): but we're seeing some rotation here back into more traditional blue chip and defensive stocks. So is Australia becoming a safe haven, or are we simply yet to feel the full impact? of the global sell-off? Let's join Grady Wolfe from Bell Direct to unpack what is driving markets and where investors should be looking this week. Good morning, Grady.
0:59
Unidentified speaker (speaker_2): Good morning, Juliet.
1:01
Unidentified speaker (speaker_1): So let's talk about last week, the midterms, you know, all of the I guess worries that we saw on Wall Street. Um Talk us through how you saw it.
1:11
Unidentified speaker (speaker_2): Yeah, last week was a bit of a slide midweek, and especially on the AI front, because not only do we have investors questioning valuations and when we're going to see returns from the high capex and outlay that we're seeing, or capital outlay we're seeing into these AI data center build outs. But now with the wave of blue that came from the midterms, it's now
1:30
Unidentified speaker (speaker_2): questioning how much more regulatory scrutiny there's going to be, policy shifts affecting AI infrastructure and data center build-out. build out. Texas is a massive uh home for where these data centers are going to be built, and now that is a blue state, which is uh was a major shock to the world, but that is exactly what we saw happen as a result of the midterm. So,
1:51
Unidentified speaker (speaker_2): a lot of potential and a lot of um question is now coming whether these and not only can the AI evaluations continue to grow and get that when we're gonna see the results and the earnings come through, but now. how much of them are gonna be built out or if they're not gonna if they're gonna stop building out. So there's a lot of question around that. So investors are really kind of taking
2:10
Unidentified speaker (speaker_2): this step back and going, is the AI story really kind of there or is it growth expectations to profitability or are they never gonna happen? So whilst they will probably still happen, there's just a lot more scrutiny to face right now in the US. So I think um we'll see a shift on that front this week, and hence why the Nasdaq was down 3.4%
2:31
Unidentified speaker (speaker_2): last week. So we're heading for a choppy start heading into the US markets this week. But it'll be really interesting to see some key results out as well this week for the AI uh front as well in the US. I think we've got core weave coming out and a few other um stocks as well. So just to see when the earnings will come through.
2:47
Unidentified speaker (speaker_1): And then here locally, because you know, we sort of been haven't been able to ride. this tech wave, but now maybe we're looking a bit more of a defensive safe haven play, perhaps.
2:56
Unidentified speaker (speaker_2): Yeah, absolutely. Now, Australia, obviously, we've had um the earnings growth in our most recent of results was really kind of lackluster. And you look at the outlook and it's a kind of seven to nine percent growth, or like low single-digit earnings growth in Australia, whereas the US markets in their most recent earnings results was 30.8, I think it was. on average as
3:16
Unidentified speaker (speaker_2): growth potential. So you look at that and you go, okay, Australia's earnings are really kind of facing that headwind. We're facing a lot of headwinds right now. But now we're seeing investors go, you know what, are the earnings growth potential going to continue sliding in the US? Is the outlook really there for the AI investment to turn around? Maybe Australia is the next opportunity because we've pulled back so far. But
3:36
Unidentified speaker (speaker_2): we're seeing investors really shift from this growth. outlook to obviously defensive stocks and consumer staples really outperformed last week with up 1.4%.
3:46
Unidentified speaker (speaker_2): Higher interest rates definitely remain the concern for consumers, businesses, and rate-sensitive sectors. So obviously, retailers like David Jones going under doesn't really bode well for the retail sector. Consumer spending is down. RBA raised rates last Tuesday. So I think investors like the longer-term longer opportunity. term opportunities in infrastructure, electrification, AI are really
4:06
Unidentified speaker (speaker_2): there. But right now we've got this volatility of the consumer facing sectors really under pressure. All of us Australians are really doing our hard right now. We've got higher rates for longer, inflation, unemployment, all of these things are really up against us. So investors are really looking for the defensive plays right now and defensive investing for kind of
4:26
Unidentified speaker (speaker_2): security. in the market as opposed to just kind of getting out all together. So I think this week will be a big one because we've got some key earnings coming out.
4:34
Unidentified speaker (speaker_1): Yeah, absolutely. So what are the key things that we should be watching out for this week?
4:38
Unidentified speaker (speaker_2): Yeah we've got ANZ and CBA coming out. Obviously we've had Westpac and NAB already come out. They have some job cuts. They've got they've said that headwinds are coming and CBA will be a big focus this week and Matt Common obviously the most recent results said that there is challenging times to come, despite that $11 billion profit that they did report. So Australia's biggest bank, um, it'll be really interesting to
4:58
Unidentified speaker (speaker_2): see exactly how hard the first quarter was for a CBA in the results coming out on November the 11th. Um, we'll be watching banking margins, mortgage competition, obviously provisions as well, because a lot of Australians, we know switching is really high. A lot of Australians are forced to refinance right now because of how. hard it is with those interest rates at 18-year
5:18
Unidentified speaker (speaker_2): highs. But lending growth, these are key drivers of earnings for our big banks. So it'll be really interesting to see how net interest margin has fared for CBA and the outlook for net interest margin, which is where they make their interest and on their outlays versus incomings. Um, And then as opposed to how much we're seeing provisions rise as well. So
5:38
Unidentified speaker (speaker_2): it'll be interesting. to see if the rise in net interest margins can offset the amount that they are losing to uh competitions in mortgages.
5:45
Unidentified speaker (speaker_1): And any other stocks on your radar?
5:48
Unidentified speaker (speaker_2): Yeah, we've got two at the moment. Obviously, it's a stockpickers market because it's such a hard time right now, and it's uh obviously every sector is doing it tough. So it's definitely there's some standout opportunities in different sectors. So Light and Wonder is one that we've got to buy a buyer rating on. We've sort
6:02
Unidentified speaker (UNKNOWN): of
6:03
Unidentified speaker (speaker_2): seen the valuation come back quite a bit recently. It's trading at just nine times EV to E bit dah, which offers compelling value in our opinion, because in times that it's really tough in the market in the world, a lot of people actually turn to gambling, which is a common fact and statistic in the world. And a lot of people see that they're at rock bottom, so they just see, why not just kind of gamble my
6:23
Unidentified speaker (speaker_2): bets and see if I can win big? So we've they've got a really strong gaming business. It's well positioned to drive growth into CY27, supported by growing North American installation base. So they install all these gaming machines and they rent them out. So that's one division of their uh of their business, and then they've got the online as well, and they've got their sales of their
6:42
Unidentified speaker (speaker_2): machines. So there's a like it's diversified earnings across the company. They've got improving profitability, their internal, uh their eBitDarbit eBitDAR beat internal. expectations by 5%. Strong cash flow generation, free cash flow increase 33%, declining debts, they're paying off debt, which is really important in the high interest rate environment. We've
7:02
Unidentified speaker (speaker_2): seen some temporary weakness at the moment with their side play currently underperforming, but we're seeing the core gaming business remains well positioned to offset that weakness that we're seeing play through. So overall, we have seen a bit of a pullback in the share price in this company, but we see that there's improving outlook, strong cash flow, and they're really um getting that down to control as well.
7:22
Unidentified speaker (speaker_2): So the longer term outlook is for strong growth, and we like the company in Light and Wonder. And then in the healthcare space, we've got Nurin, which um is a company we've been really bullish on for quite some Sometime time, and it's gone from strength to strength. So the company is um it's they came up with the world's first. treatment for Rhett syndrome, the rare neurodevelopmental disorder. So
7:42
Unidentified speaker (speaker_2): Q3 sales uh for Deboo, which is the drug that uh treats Rhett syndrome globally, increased 39%. Um, and that was 12% quarter on quarter, so $140 million in revenues there or sales, and um that beat expectations as well. So their partner is Arcadia Pharmaceuticals, so they get the um
8:03
Unidentified speaker (speaker_2): they've got the combined sales there. So they get the clip of the ticket from that. The strong product adoption, over the 50% of the US have now transitioned to this new powdered formula. So they brought out a powdered formula as well. So obviously that's um being really well approved and accepted in that market. They've upgraded their earnings again for FY26. So in the first
8:22
Unidentified speaker (speaker_2): quarter and second quarter, so second consecutive quarter, they've increased their earnings. which is very rare for a company to do. As we know, a lot of companies are failing to put out guidance at the moment because of the such uncertain times. But Nuron continues to go from strength to strength and increase that. So their partner also, Arcadia, reaffirmed its debut sales
8:42
Unidentified speaker (speaker_2): target for 2028, being 700 million US dollars. So really strong long-term growth opportunities there. They're also launching a into Germany, triggering a milestone payment. And the best thing about this company right now is whilst they do have that first drug, debut drug, in the market, treating Rett syndrome, already bringing in
9:02
Unidentified speaker (speaker_2): sales and money, they've got a second drug on uh in phase three trials right now, NNZ251. And that's for the treatment of five neurodevelopmental disorders. No, sorry, four neurodevelopmental disorders. that currently don't have a treatment in the market. So Debut treats Rhett syndrome, that's one neurodevelopmental disorder. And this one,
9:22
Unidentified speaker (speaker_2): the next drug, treats four, and they're kind of expecting the drug their market to be five times that of their first drug or debut drug. So you look at that and you go, at the moment, none of those potential future earnings are factored into the share price. So you're effectively getting it for free.
9:39
Unidentified speaker (speaker_2): So we like the look of neuron and um, especially on a long-term growth front.
9:44
Unidentified speaker (speaker_1): All right, Grady. Great to get some stop picks and a look at the week that should be. Thank you so much, Grady Wolf from Bell Direct.
9:51
Unidentified speaker (speaker_2): Thanks for having me.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.

More from ausbiz a.m

ausbiz a.m

18.11.26 Annabelle Miller, ECP Asset Management

Episode discussion: ECP's Miller sees rotation from megacap tech to Japan and Korea; NVIDIA leadership scrutiny

Speakers’ claims: Annabelle Miller of ECP Asset Management discusses a market rotation away from megacap tech into other sectors, citing NVIDIA's leadership transition and cyber incidents as key factors. She highlights the Anthropic IPO's retail allocation mechanics and Apple's role as a defensive hedge. Miller also outlines investment opportunities in Japanese equities like Nintendo and South Korean healthcare, arguing that memory price cycles and index weighting distortions create value.

NVIDIAAI EcosystemRetail IPOs
8 min3 assets10 claims to verify
ausbiz a.m

17.11.26 Jack Stickley, Morgans

Episode discussion: Jack Stickley discusses AI sell-off, NVIDIA catalyst, and resilient Australian banks

Speakers’ claims: Jack Stickley of Morgans notes that the ASX is expected to dip following a sharp sell-off in US tech and semi stocks, driven largely by NVIDIA's upcoming earnings and broader geopolitical tensions. He highlights that while the semiconductor index has fallen over 10% since the midterm elections, NVIDIA remains a critical AI supply chain leader despite losing over a trillion dollars in market cap. Stickley describes the Australian market as resilient due to stable income-generating sectors like banks and resources, which are benefiting from AI-driven cost reductions despite high interest rates. He also points to emerging value in Australian SaaS stocks like Xero, which are using AI to improve efficiency rather than being disrupted by it. Finally, he suggests that high-quality consumer names could rebound if interest rates peak, while property trusts remain on hold.

NVIDIAAustralian BanksAI Disruption
12 min7 assets10 claims to verify
All insights